...
首页> 外文期刊>Lipids in Health Disease >Treatment of an adrenomyeloneuropathy patient with Lorenzo's oil and supplementation with docosahexaenoic acid-A case report
【24h】

Treatment of an adrenomyeloneuropathy patient with Lorenzo's oil and supplementation with docosahexaenoic acid-A case report

机译:洛伦佐油治疗并补充二十二碳六烯酸治疗肾上腺皮质激素神经病患者一例

获取原文

摘要

This is a case report of adrenomyeloneuropathy (AMN), the adult variant of adrenoleukodystryphy (ALD). The diagnoses in the patient, aged 34, was confirmed via increased serum very long chain fatty acid concentration (VLCFA). Treatment started with the cholesterol lowering drug, atorvastatin, followed by add-on therapy with Lorenzo's oil (LO) and finally supplementation with docosahexaenoic acid (DHA). The magnetic resonance imaging (MRI) scan of the AMN patient before DHA treatment, already showed abnormal white matter in the brain. Although the MRI showed no neurological improvement after 6 months of DHA treatment, no selective progression of demyelination was detected in the AMN patient. Contrary to what was expected, LO failed to sustain or normalize the VLCFA levels or improve clinical symptoms. It was however, shown that DHA supplementation in addition to LO, increased DHA levels in both plasma and red blood cells (RBC). Additionally, the study showed evidence that the elongase activity in the elongation of eicosapentaenoic acid (EPA) to docosapentaenoic acid (DPA) might have been significantly compromised, due to the increased DHA levels.
机译:这是肾上腺髓质神经病(ALD)的成人变体肾上腺髓质神经病(AMN)的病例报告。通过增加血清极长链脂肪酸浓度(VLCFA)证实了该患者的诊断年龄为34岁。治疗先从降低胆固醇的药物阿托伐他汀开始,然后再用洛伦佐油(LO)进行附加治疗,最后补充二十二碳六烯酸(DHA)。在DHA治疗之前,对AMN患者的磁共振成像(MRI)扫描已经显示出大脑中的异常白质。尽管MRI在DHA治疗6个月后未显示神经功能改善,但在AMN患者中未发现脱髓鞘的选择性进展。与预期相反,LO无法维持或正常化VLCFA水平或改善临床症状。然而,结果表明,除LO外,补充DHA还增加了血浆和红细胞(RBC)中的DHA水平。此外,该研究表明,由于DHA含量的增加,二十碳五烯酸(EPA)向二十二碳五烯酸(DPA)的延伸率中的延伸酶活性可能受到了很大影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号